ANIP Stock Analysis: ANI Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.934m USD | 12M Return: 24.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.2M
EPS Trend: 52.2%
Qual. Beats: 1
Rev. Trend: 99.4%
Qual. Beats: 6
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a U.S.-based biopharmaceutical company incorporated in 2001 and headquartered in Baudette, Minnesota. The company develops, manufactures, and markets both branded and generic prescription pharmaceutical products, selling primarily in the United States with some international reach.
Its product portfolio spans multiple dosage forms and therapeutic categories, including injectable generics, softgel capsules, oral solid doses, semi-solids, liquids, topicals, controlled substances, and potent compounds. On the branded side, the company markets specialty products such as Cortrophin gel, ILUVIEN, and YUTIQ, which are typically sold into narrower physician- or hospital-based channels than its generics.
ANI distributes through a diversified channel mix that includes national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. This dual model - high-volume generic manufacturing combined with niche branded specialty drugs - exposes the company to both competitive generic pricing pressure and the higher-margin dynamics typical of branded specialty pharmaceuticals, including longer exclusivity windows and FDA orphan-drug protections on select products.
- Cortrophin gel prescriptions drive branded revenue growth
- Generic pricing pressure weighs on margins
- ILUVIEN and YUTIQ acquisitions expand rare disease portfolio
| Net Income: 89.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 7.47 > 1.0 |
| NWC/Revenue: 54.95% < 20% (prev 49.62%; Δ 5.33% < -1%) |
| CFO/TA 0.15 > 3% & CFO 208.6m > Net Income 89.7m |
| Net Debt (302.6m) to EBITDA (234.7m): 1.29 < 3 |
| Current Ratio: 3.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (21.5m) vs 12m ago 7.47% < -2% |
| Gross Margin: 65.94% > 18% (prev 59.34%; Δ 6.60% > 0.5%) |
| Asset Turnover: 68.06% > 50% (prev 52.16%; Δ 15.90% > 0%) |
| Interest Coverage Ratio: 3.67 > 6 (EBIT TTM 145.3m / Interest Expense TTM 39.6m) |
| A: 0.36 (Total Current Assets 747.1m - Total Current Liabilities 239.5m) / Total Assets 1.42b |
| B: 0.00 (Retained Earnings 6.39m / Total Assets 1.42b) |
| C: 0.11 (EBIT TTM 145.3m / Avg Total Assets 1.36b) |
| D: 0.65 (Book Value of Equity 562.3m / Total Liabilities 859.7m) |
| Altman-Z'' = 3.76 = AA |
| DSRI: 0.85 (Receivables 255.4m/220.3m, Revenue 923.7m/674.1m) |
| GMI: 0.90 (GM 59.34% / 65.94%) |
| AQI: 0.79 (AQ_t 0.43 / AQ_t-1 0.54) |
| SGI: 1.37 (Revenue 923.7m / 674.1m) |
| TATA: -0.08 (NI 89.7m - CFO 208.6m) / TA 1.42b) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 81.08 with a total of 303,406 shares traded. Over the past week, the price has changed by -4.67%, over one month by -1.47%, over three months by +3.54% and over the past year by +24.37%.
Current recommended Stop Loss: 75.10 (which is 7.4% or 2.3 ATR below the current price).
ANI Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ANIP.
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 112.7 | 39% |
P/E Trailing = 21.7519
P/E Forward = 10.4167
P/S = 2.0933
P/B = 3.4783
P/EG = 1.06
Revenue TTM = 923.7m USD
EBIT TTM = 145.3m USD
EBITDA TTM = 234.7m USD
Long Term Debt = 594.5m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 613.8m USD (corrected: LT Debt 594.5m + ST Debt 19.3m)
Net Debt = 302.6m USD (calculated: Debt 613.8m - CCE 311.2m)
Enterprise Value = 2.24b USD (1.93b + Debt 613.8m - CCE 311.2m)
Interest Coverage Ratio = 3.67 (Ebit TTM 145.3m / Interest Expense TTM 39.6m)
EV/FCF = 13.95x (Enterprise Value 2.24b / FCF TTM 160.4m)
FCF Yield = 7.17% (FCF TTM 160.4m / Enterprise Value 2.24b)
FCF Margin = 17.36% (FCF TTM 160.4m / Revenue TTM 923.7m)
Net Margin = 9.71% (Net Income TTM 89.7m / Revenue TTM 923.7m)
Gross Margin = 65.94% ((Revenue TTM 923.7m - Cost of Revenue TTM 314.6m) / Revenue TTM)
Gross Margin QoQ = 51.78% (prev none%)
Tobins Q-Ratio = 1.57 (Enterprise Value 2.24b / Total Assets 1.42b)
Interest Expense / Debt = 6.45% (Interest Expense 39.6m / Debt 613.8m)
Taxrate = 20.58% (23.9m / 116.0m)
NOPAT = 115.4m (EBIT 145.3m * (1 - 20.58%))
Current Ratio = 3.12 (Total Current Assets 747.1m / Total Current Liabilities 239.5m)
Debt / Equity = 1.09 (Debt 613.8m / totalStockholderEquity, last quarter 562.3m)
Debt / EBITDA = 1.29 (Net Debt 302.6m / EBITDA 234.7m)
Debt / FCF = 1.89 (Net Debt 302.6m / FCF TTM 160.4m)
Total Stockholder Equity = 517.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.61% (Net Income 89.7m / Total Assets 1.42b)
RoE = 17.32% (Net Income TTM 89.7m / Total Stockholder Equity 517.6m)
RoCE = 13.06% (EBIT 145.3m / Capital Employed (Equity 517.6m + L.T.Debt 594.5m))
RoIC = 9.98% (NOPAT 115.4m / Invested Capital 1.16b)
WACC = 6.68% (E(1.93b)/V(2.55b) * Re(7.17%) + D(613.8m)/V(2.55b) * Rd(6.45%) * (1-Tc(0.21)))
Discount Rate = 7.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.19 | Cagr: 5.21%
[DCF] Terminal Value 77.97% ; FCFF base≈115.9m ; Y1≈132.8m ; Y5≈195.5m
[DCF] Fair Price = 116.1 (EV 2.94b - Net Debt 302.6m = Equity 2.64b / Shares 22.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 52.19 | EPS CAGR: 17.64% | SUE: 1.80 | # QB: 1
Revenue Correlation: 99.39 | Revenue CAGR: 35.21% | SUE: 4.0 | # QB: 6
EPS current Quarter (2026-06-30): EPS=2.01 | Chg30d=+0.51% | Revisions=-44% | Analysts=6
EPS next Quarter (2026-09-30): EPS=2.50 | Chg30d=-0.60% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=9.37 | Chg30d=-0.51% | Revisions=+70% | GrowthEPS=+18.7% | GrowthRev=+26.5%
EPS next Year (2027-12-31): EPS=10.69 | Chg30d=-0.18% | Revisions=-30% | GrowthEPS=+14.2% | GrowthRev=+11.3%
[Analyst] Revisions Ratio: +0% (up=13, down=13)